Which has stronger valuation and earnings, ENGN or KYNB?

Kyntra Bio has higher revenue and earnings than enGene. enGene is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio enGene N/A N/A -$117.30M -$2.17 N/A Kyntra Bio $6.44M 4.43 $183.45M $45.30 0.16

Is ENGN or KYNB more profitable?

Kyntra Bio has a net margin of 2,199.13% compared to enGene's net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat enGene's return on equity. Company Net Margins Return on Equity Return on Assets enGene N/A -56.06% -45.64% Kyntra Bio 2,199.13% N/A -45.24%

Does the media prefer ENGN or KYNB?

In the previous week, enGene had 8 more articles in the media than Kyntra Bio. MarketBeat recorded 13 mentions for enGene and 5 mentions for Kyntra Bio. Kyntra Bio's average media sentiment score of 0.64 beat enGene's score of 0.09 indicating that Kyntra Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment enGene 1 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Kyntra Bio 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend KYNB or LIXT?

Kyntra Bio currently has a consensus price target of $32.50, suggesting a potential upside of 360.99%. Given Kyntra Bio's stronger consensus rating and higher probable upside, analysts clearly believe Kyntra Bio is more favorable than Lixte Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kyntra Bio 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60 Lixte Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor KYNB or LIXT?

In the previous week, Kyntra Bio had 4 more articles in the media than Lixte Biotechnology. MarketBeat recorded 5 mentions for Kyntra Bio and 1 mentions for Lixte Biotechnology. Lixte Biotechnology's average media sentiment score of 0.69 beat Kyntra Bio's score of 0.64 indicating that Lixte Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyntra Bio 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lixte Biotechnology 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor KYNB or COYA?

In the previous week, Coya Therapeutics had 7 more articles in the media than Kyntra Bio. MarketBeat recorded 12 mentions for Coya Therapeutics and 5 mentions for Kyntra Bio. Kyntra Bio's average media sentiment score of 0.64 beat Coya Therapeutics' score of 0.38 indicating that Kyntra Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyntra Bio 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Coya Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, GUTS or KYNB?

Kyntra Bio has higher revenue and earnings than Fractyl Health. Fractyl Health is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Fractyl Health $90K 1,202.69 -$140.95M -$0.88 N/A Kyntra Bio $6.44M 4.43 $183.45M $45.30 0.16

Is GUTS or KYNB more profitable?

Kyntra Bio has a net margin of 2,199.13% compared to Fractyl Health's net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat Fractyl Health's return on equity. Company Net Margins Return on Equity Return on Assets Fractyl Health N/A -1,362.10% -84.89% Kyntra Bio 2,199.13% N/A -45.24%

Does the media prefer GUTS or KYNB?

In the previous week, Fractyl Health had 17 more articles in the media than Kyntra Bio. MarketBeat recorded 22 mentions for Fractyl Health and 5 mentions for Kyntra Bio. Fractyl Health's average media sentiment score of 0.75 beat Kyntra Bio's score of 0.64 indicating that Fractyl Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fractyl Health 2 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Kyntra Bio 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Kyntra Bio (KYNB) Competitors

$7.05 +0.01 (+0.14%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$7.05 0.00 (0.00%)

As of 08/14/2026 07:55 PM Eastern

Compare

KYNB vs. ENGN, LIXT, COYA, ANIX, and GUTS

Should you buy Kyntra Bio stock or one of its competitors? Kyntra Bio's main competitors and comparable companies include enGene (ENGN), Lixte Biotechnology (LIXT), Coya Therapeutics (COYA), Anixa Biosciences (ANIX), and Fractyl Health (GUTS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Kyntra Bio compare to enGene?

enGene (NASDAQ:ENGN) and Kyntra Bio (NASDAQ:KYNB) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

enGene presently has a consensus price target of $11.05, indicating a potential upside of 549.73%. Kyntra Bio has a consensus price target of $32.50, indicating a potential upside of 360.99%. Given enGene's higher possible upside, equities research analysts plainly believe enGene is more favorable than Kyntra Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

64.2% of enGene shares are owned by institutional investors. Comparatively, 72.7% of Kyntra Bio shares are owned by institutional investors. 10.5% of enGene shares are owned by insiders. Comparatively, 4.2% of Kyntra Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Kyntra Bio has a net margin of 2,199.13% compared to enGene's net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat enGene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-56.06%	-45.64%
Kyntra Bio	2,199.13%	N/A	-45.24%

enGene has a beta of -0.28, indicating that its share price is 128% less volatile than the broader market. Comparatively, Kyntra Bio has a beta of 1.02, indicating that its share price is 2% more volatile than the broader market.

Kyntra Bio has higher revenue and earnings than enGene. enGene is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$117.30M	-$2.17	N/A
Kyntra Bio	$6.44M	4.43	$183.45M	$45.30	0.16

In the previous week, enGene had 8 more articles in the media than Kyntra Bio. MarketBeat recorded 13 mentions for enGene and 5 mentions for Kyntra Bio. Kyntra Bio's average media sentiment score of 0.64 beat enGene's score of 0.09 indicating that Kyntra Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
enGene	1 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Kyntra Bio	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Kyntra Bio beats enGene on 12 of the 16 factors compared between the two stocks.

How does Kyntra Bio compare to Lixte Biotechnology?

Kyntra Bio (NASDAQ:KYNB) and Lixte Biotechnology (NASDAQ:LIXT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability, analyst recommendations and media sentiment.

Kyntra Bio has higher revenue and earnings than Lixte Biotechnology. Lixte Biotechnology is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyntra Bio	$6.44M	4.43	$183.45M	$45.30	0.16
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.13	N/A

Kyntra Bio has a net margin of 2,199.13% compared to Lixte Biotechnology's net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat Lixte Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyntra Bio	2,199.13%	N/A	-45.24%
Lixte Biotechnology	N/A	-134.91%	-95.61%

72.7% of Kyntra Bio shares are held by institutional investors. Comparatively, 5.1% of Lixte Biotechnology shares are held by institutional investors. 4.2% of Kyntra Bio shares are held by company insiders. Comparatively, 9.5% of Lixte Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Kyntra Bio has a beta of 1.02, meaning that its share price is 2% more volatile than the broader market. Comparatively, Lixte Biotechnology has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market.

In the previous week, Kyntra Bio had 4 more articles in the media than Lixte Biotechnology. MarketBeat recorded 5 mentions for Kyntra Bio and 1 mentions for Lixte Biotechnology. Lixte Biotechnology's average media sentiment score of 0.69 beat Kyntra Bio's score of 0.64 indicating that Lixte Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyntra Bio	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lixte Biotechnology	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kyntra Bio currently has a consensus price target of $32.50, suggesting a potential upside of 360.99%. Given Kyntra Bio's stronger consensus rating and higher probable upside, analysts clearly believe Kyntra Bio is more favorable than Lixte Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Kyntra Bio beats Lixte Biotechnology on 13 of the 16 factors compared between the two stocks.

How does Kyntra Bio compare to Coya Therapeutics?

Kyntra Bio (NASDAQ:KYNB) and Coya Therapeutics (NASDAQ:COYA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Kyntra Bio has a beta of 1.02, indicating that its stock price is 2% more volatile than the broader market. Comparatively, Coya Therapeutics has a beta of 0.6, indicating that its stock price is 40% less volatile than the broader market.

In the previous week, Coya Therapeutics had 7 more articles in the media than Kyntra Bio. MarketBeat recorded 12 mentions for Coya Therapeutics and 5 mentions for Kyntra Bio. Kyntra Bio's average media sentiment score of 0.64 beat Coya Therapeutics' score of 0.38 indicating that Kyntra Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyntra Bio	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Coya Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kyntra Bio currently has a consensus price target of $32.50, indicating a potential upside of 360.99%. Coya Therapeutics has a consensus price target of $15.33, indicating a potential upside of 220.11%. Given Kyntra Bio's higher probable upside, equities research analysts clearly believe Kyntra Bio is more favorable than Coya Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Kyntra Bio has higher earnings, but lower revenue than Coya Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyntra Bio	$6.44M	4.43	$183.45M	$45.30	0.16
Coya Therapeutics	$8.02M	14.01	-$21.23M	-$1.07	N/A

Kyntra Bio has a net margin of 2,199.13% compared to Coya Therapeutics' net margin of -270.22%. Kyntra Bio's return on equity of 0.00% beat Coya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyntra Bio	2,199.13%	N/A	-45.24%
Coya Therapeutics	-270.22%	-52.05%	-46.34%

72.7% of Kyntra Bio shares are owned by institutional investors. Comparatively, 39.8% of Coya Therapeutics shares are owned by institutional investors. 4.2% of Kyntra Bio shares are owned by company insiders. Comparatively, 6.1% of Coya Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Kyntra Bio beats Coya Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Kyntra Bio compare to Anixa Biosciences?

Kyntra Bio (NASDAQ:KYNB) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

Kyntra Bio has a net margin of 2,199.13% compared to Anixa Biosciences' net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat Anixa Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyntra Bio	2,199.13%	N/A	-45.24%
Anixa Biosciences	N/A	-71.12%	-62.88%

72.7% of Kyntra Bio shares are held by institutional investors. Comparatively, 29.1% of Anixa Biosciences shares are held by institutional investors. 4.2% of Kyntra Bio shares are held by company insiders. Comparatively, 26.4% of Anixa Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Kyntra Bio has higher revenue and earnings than Anixa Biosciences. Anixa Biosciences is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyntra Bio	$6.44M	4.43	$183.45M	$45.30	0.16
Anixa Biosciences	$210K	515.16	-$10.93M	-$0.31	N/A

In the previous week, Kyntra Bio had 4 more articles in the media than Anixa Biosciences. MarketBeat recorded 5 mentions for Kyntra Bio and 1 mentions for Anixa Biosciences. Anixa Biosciences' average media sentiment score of 1.89 beat Kyntra Bio's score of 0.64 indicating that Anixa Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Kyntra Bio	Positive
Anixa Biosciences	Very Positive

Kyntra Bio currently has a consensus price target of $32.50, suggesting a potential upside of 360.99%. Anixa Biosciences has a consensus price target of $8.50, suggesting a potential upside of 167.30%. Given Kyntra Bio's higher probable upside, equities research analysts plainly believe Kyntra Bio is more favorable than Anixa Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Anixa Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Kyntra Bio has a beta of 1.02, indicating that its stock price is 2% more volatile than the broader market. Comparatively, Anixa Biosciences has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market.

Summary

Kyntra Bio beats Anixa Biosciences on 11 of the 16 factors compared between the two stocks.

How does Kyntra Bio compare to Fractyl Health?

Fractyl Health (NASDAQ:GUTS) and Kyntra Bio (NASDAQ:KYNB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends.

72.7% of Kyntra Bio shares are owned by institutional investors. 8.5% of Fractyl Health shares are owned by insiders. Comparatively, 4.2% of Kyntra Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Fractyl Health has a beta of 2.32, suggesting that its stock price is 132% more volatile than the broader market. Comparatively, Kyntra Bio has a beta of 1.02, suggesting that its stock price is 2% more volatile than the broader market.

Kyntra Bio has a net margin of 2,199.13% compared to Fractyl Health's net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat Fractyl Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fractyl Health	N/A	-1,362.10%	-84.89%
Kyntra Bio	2,199.13%	N/A	-45.24%

In the previous week, Fractyl Health had 17 more articles in the media than Kyntra Bio. MarketBeat recorded 22 mentions for Fractyl Health and 5 mentions for Kyntra Bio. Fractyl Health's average media sentiment score of 0.75 beat Kyntra Bio's score of 0.64 indicating that Fractyl Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fractyl Health	2 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Kyntra Bio	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Fractyl Health currently has a consensus price target of $5.12, indicating a potential upside of 652.94%. Kyntra Bio has a consensus price target of $32.50, indicating a potential upside of 360.99%. Given Fractyl Health's higher probable upside, equities analysts plainly believe Fractyl Health is more favorable than Kyntra Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fractyl Health	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Kyntra Bio has higher revenue and earnings than Fractyl Health. Fractyl Health is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fractyl Health	$90K	1,202.69	-$140.95M	-$0.88	N/A
Kyntra Bio	$6.44M	4.43	$183.45M	$45.30	0.16

Summary

Kyntra Bio beats Fractyl Health on 10 of the 17 factors compared between the two stocks.

Get Kyntra Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KYNB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KYNB vs. The Competition

Export

Metric	Kyntra Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$28.54M	$3.72B	$7.03B	$13.07B
Dividend Yield	N/A	3.69%	2.57%	10.65%
P/E Ratio	0.16	10.77	271.26	25.37
Price / Sales	4.43	1,363.59	622.96	106.04
Price / Cash	N/A	101.42	75.70	53.27
Price / Book	-1.68	16.78	12.92	6.21
Net Income	$183.45M	-$13.32M	$3.45B	$347.71M
7 Day Performance	-3.03%	1.76%	1.16%	1.08%
1 Month Performance	-2.22%	1.14%	1.37%	0.82%
1 Year Performance	N/A	54.35%	62.53%	20.99%

Kyntra Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KYNB Kyntra Bio	3.3448 of 5 stars	$7.05 +0.1%	$32.50 +361.0%	N/A	$28.54M	$6.44M	0.16	570	News Coverage High Trading Volume
ENGN enGene	3.0374 of 5 stars	$1.70 +0.6%	$11.05 +549.7%	-52.9%	$113.21M	N/A	N/A	31	Analyst Forecast
LIXT Lixte Biotechnology	0.0657 of 5 stars	$7.51 +4.2%	N/A	+92.6%	$112.80M	N/A	N/A	4	News Coverage Gap Up
COYA Coya Therapeutics	2.1492 of 5 stars	$4.79 +2.6%	$15.33 +220.1%	-15.7%	$109.55M	$7.95M	N/A	6	News Coverage Earnings Report Analyst Forecast
ANIX Anixa Biosciences	4.4429 of 5 stars	$3.18 -0.6%	$8.50 +167.3%	+7.1%	$108.87M	$210K	N/A	5	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KYNB) was last updated on 8/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kyntra Bio (KYNB) Competitors

KYNB vs. ENGN, LIXT, COYA, ANIX, and GUTS

How does Kyntra Bio compare to enGene?

Summary

How does Kyntra Bio compare to Lixte Biotechnology?

Summary

How does Kyntra Bio compare to Coya Therapeutics?

Summary

How does Kyntra Bio compare to Anixa Biosciences?

Summary

How does Kyntra Bio compare to Fractyl Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYNB vs. The Competition

Kyntra Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kyntra Bio (KYNB) Competitors

KYNB vs. ENGN, LIXT, COYA, ANIX, and GUTS

How does Kyntra Bio compare to enGene?

Do analysts prefer ENGN or KYNB?

Do insiders and institutionals have more ownership in ENGN or KYNB?

Is ENGN or KYNB more profitable?

Which has more volatility and risk, ENGN or KYNB?

Which has stronger valuation and earnings, ENGN or KYNB?

Does the media prefer ENGN or KYNB?

Summary

How does Kyntra Bio compare to Lixte Biotechnology?

Which has preferable valuation and earnings, KYNB or LIXT?

Is KYNB or LIXT more profitable?

Do institutionals and insiders hold more shares of KYNB or LIXT?

Which has more risk & volatility, KYNB or LIXT?

Does the media favor KYNB or LIXT?

Do analysts recommend KYNB or LIXT?

Summary

How does Kyntra Bio compare to Coya Therapeutics?

Which has more risk and volatility, KYNB or COYA?

Does the media favor KYNB or COYA?

Do analysts recommend KYNB or COYA?

Which has better valuation and earnings, KYNB or COYA?

Is KYNB or COYA more profitable?

Do insiders & institutionals believe in KYNB or COYA?

Summary

How does Kyntra Bio compare to Anixa Biosciences?

Is KYNB or ANIX more profitable?

Do insiders & institutionals hold more shares of KYNB or ANIX?

Which has better earnings and valuation, KYNB or ANIX?

Does the media refer more to KYNB or ANIX?

Do analysts recommend KYNB or ANIX?

Which has more risk and volatility, KYNB or ANIX?

Summary

How does Kyntra Bio compare to Fractyl Health?

Do insiders and institutionals have more ownership in GUTS or KYNB?

Which has more risk & volatility, GUTS or KYNB?

Is GUTS or KYNB more profitable?

Does the media prefer GUTS or KYNB?

Do analysts recommend GUTS or KYNB?

Which has better earnings and valuation, GUTS or KYNB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYNB vs. The Competition

Kyntra Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools